anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To provide oyster shell fine powder having a high acid-controlling effect.  <P>SOLUTION: The oyster shell fine powder is obtained by crushing the oyster shell powder by a super fine pulverizer and having 0.05 to 10 μm mean particle size. The oyster shell fine powder may be formed e.g. by accelerating the oyster shell powder with a high pressure gas energy to super finely pulverize in nano level caused by inter-particle collisions. The oyster shell fine particles may be contained e.g. in an acid-controlling composition. The acid-controlling composition can be used as a digestive medicine.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Polatuzumab vedotin will be given in conjunction with 6 cycles of R-EPCH (rituximab, etoposide, prednisone, cyclophosphamide, hydroxydaunorubicin). The dosing schedule and regimen for R-EPCH will follow established protocols. Polatuzumab vedotin will be administered on Day 1 of each 21-day cycle.
BACKGROUND: Sex disparities exist in cardiometabolic diseases. Metabolomic profiling offers insight into disease mechanisms, as the metabolome is influenced by environmental and genetic factors. We identified metabolites associated with sex and determined if sex-associated metabolites are associated with incident stoke, incident coronary heart disease, prevalent hypertension, and prevalent chronic kidney disease.
METHODS AND RESULTS: Targeted metabolomics was conducted for 357 metabolites in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) case-cohort substudy for incident stroke. Weighted logistic regression models were used to identify metabolites associated with sex in REGARDS. Sex-associated metabolites were replicated in the HyperGEN (Hypertension Genetic Epidemiology Network) and using the literature. Weighted Cox proportional hazard models were used to evaluate associations between metabolites and incident stroke. Cox proportional hazard models were used to evaluate associations between metabolites and incident coronary heart disease. Weighted logistic regression models were used to evaluate associations between metabolites and hypertension and chronic kidney disease. Fifty-one replicated metabolites were associated with sex. Higher levels of 6 phosphatidylethanolamines were associated with incident stroke. No metabolites were associated with incident coronary heart disease. Higher levels of uric acid and leucine and lower levels of a lysophosphatidylcholine were associated with hypertension. Higher levels of indole-3-lactic acid, 7 phosphatidylethanolamines, and uric acid, and lower levels of betaine and bilirubin were associated with chronic kidney disease.
CONCLUSIONS: These findings suggest that the sexual dimorphism of the metabolome may contribute to sex differences in stroke, hypertension, and chronic kidney disease.
The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.
For Short Surgical Procedures

The average dose required to produce neuromuscular blockade and to facilitate tracheal intubation is 0.6 mg/kg ANECTINE given intravenously. The optimum intravenous dose will vary among patients and may be from 0.3 to 1.1 mg/kg for adults. Following intravenous administration of doses in this range, neuromuscular blockade develops in about 1 minute; maximum blockade may persist for about 2 minutes, after which recovery takes place within 4 to 6 minutes. Depending on the dose and duration of succinylcholine administration, the characteristic depolarizing neuromuscular block (Phase I block) may change to a block with characteristics superficially resembling a non-depolarizing block (Phase II block) [see Prolonged Neuromuscular Block due to Phase II Block and Tachyphylaxis (5.8), Overdose (10), and Pharmacodynamics (12.2)]. A 5 to 10 mg test dose may be used to determine the sensitivity of the patient and the individual recovery time [see Warnings and Precautions (5.9)].

For Long Surgical Procedures

Continuous Intravenous Infusion

The dose of ANECTINE administered by intravenous infusion depends upon the duration of the surgical procedure and the need for muscle relaxation. The average rate for an adult range between 2.5 and 4.3 mg per minute.

Diluted ANECTINE solutions containing from 1 to 2 mg/mL succinylcholine have commonly been used for continuous infusion [see Dosage and Administration (2.4)]. The more dilute solution (1 mg/mL) is probably preferable from the standpoint of ease of control of the rate of administration of ANECTINE and hence, of relaxation. This diluted ANECTINE solution containing 1 mg/mL of succinylcholine may be administered at a rate of 0.5 mg (0.5 mL) to 10 mg (10 mL) per minute to obtain the required amount of relaxation. The amount required per minute will depend upon the individual response as well as the degree of relaxation require. Monitor neuromuscular function with a peripheral nerve stimulator when using ANECTINE by infusion in order to avoid overdose, detect development of Phase II block, follow its rate of recovery, and assess the effects of reversing agents [see Warnings and Precautions (5.8)].

Intermittent Intravenous Injection

Intermittent intravenous injections of ANECTINE may also be used to provide muscle relaxation for long procedures. An intravenous injection of 0.3 to 1.1 mg/kg may be given initially, followed, at appropriate intervals, by further intravenous injections of 0.04 to 0.07 mg/kg to maintain the degree of relaxation required.
Group 1 (Carbohydrate Restrictive Strategy). Patients received intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16,7% proteins and 50% lipids (Glucerna, Abbott Laboratories). These patients received regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and, in stable patients, ideally below 150 mg/dl.
The present invention relates to a composition comprising a peptide immunogen useful for the prevention and treatment of Alzheimer's Disease. More particularly, the peptide immunogen comprises a main functional/regulatory site, an N-terminal fragment of Amyloid .beta.(A.beta.) peptide linked to a helper T cell epitope (Th) having multiple class II MHX binding motifs. The peptide immunogen elicit a site--directed immune response against the main functional/regulatory site of the A.beta.  peptide and generate antibodies, which are highly cross-reactive to the soluble A.beta.1-42 peptide and the amyloid plaques formed in the brain of Alzheimer's Disease patients. The antibodies elicited being cross reactive to the soluble A.beta.1-42 peptide, promote fibril disaggregation and inhibit fibrillar aggregation leading to immunoneutralization of the "soluble A.beta.-derived toxins"; and being cross--reactive to the amyloid plaques, accelerate the clearance of these, plaques from the brain. Thus, the composition of the invention comprising the peptide immunogen is useful for the prevention and treatment of Alzheimer's Disease.
PROBLEM TO BE SOLVED: To obtain a bathing composition capable of improving slippery feeling of the skin, capable of securing moist feeling of the skin after bathing, and hardly allowing various germs to propagate even if the solution is left after the bathing by using alkaline inorganic salts except boric acid compound, in combination with the boric acid compound and a cationized polymer. SOLUTION: This bathing composition consists essentially of a boric acid compound [preferably, e.g. borax (Na2B4O7.10H2O), and at 20-70 wt.% based on the alkaline inorganic salts], and the alkaline inorganic salts (e.g. sodium carbonate) except the boric acid compound. The content of the inorganic salts based on the solution using the composition is preferably >=40 wt.% so that the pH may be alkaline of 8.0-11. A cationized polymer (e.g. a cationized cellulose) is preferably included at 0.1-20 wt.% based on the total amount of the inorganic salts and the cationized polymer.
One vaginal insert administered 18 - 24 hours prior to the scheduled hysteroscopy clinic visit. The initial dose is 400 mcg and dose will be adjusted between 100 - 1600 mcg after each study cohort based on safety and efficacy criteria as assessed by the Data and Safety Monitoring Board (DSMB).
A simplified and evidence-based algorithm for examination and treatment of patients with shoulder pain will be developed and implemented in general practice. The purpose is to improve quality of care and provide GPs with a simplified and efficient tool to handle patients with common shoulder- related pain. The study is a stepped-wedge, cluster-randomized trial with a hybrid design including a effectiveness, cost and implementation assessment of a guideline-based intervention in clinical practice (2). General practitioners in Norway will be recruited and the GP offices will be randomized to the time of crossover from current treatment as usual (TAU) to the implementation of the intervention. The intervention is a tailored strategy that includes workshops for general practitioners covering information and access to a decision support tool, an education program where the general practitioner learn an evidence-based approach to shoulder pain and access to patient information materials. Outcomes will be measured at patient and GP levels, using self-report questionnaires, focus group interviews and register based data.
PURPOSE: To obtain an injection for sustained release local anesthesia capable of maintaining a nerve block for a long period of time and continuing treating effect, containing a local anesthetics on a carrier decomposable in an organism. CONSTITUTION: A polymer compound is used as a carrier decomposable in an organism and a local anesthetics such as lidocaine is dissolved or dispersed into the carrier to prepare an infection. One or more selected from a natural polymer compound (e.g. collagen) and a synthetic polymer compound (e.g. polylactic acid) which are gradually decomposed in an organism, metabolized, have low toxicity and can be administered in an organism are used as the carrier decomposable in an organism. For example, when the natural polymer compound is used as the carrier, a local anesthetics, preferably an acid addition salt is dissolved or uniformly dispersed in an aqueous solution containing the polymer compound, mixed with a conventional component such as a thickening agent and a stabilizer and pharmaceutically manufactured by a filtration sterilization method.  The concentration of the natural polymer compound is 0.1-10wt.% and that of the local anesthetics is 0.1-30wt.%. A dose is 1-10ml.
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disease most typical in women. Generalized osteoporosis is common in RA, at axial and appendicular skeleton and in females and males. Denosumab is a fully humanized IgG monoclonal antibody that targets the receptor activator of nuclear factor κB ligand (RANKL). Denosumab prevents the binding and activation of the RANK receptors on the osteoclasts and hence inhibits osteoclasts formation, activation, function and survival. Denosumab results in more rapid and greater reductions in bone remodeling and correspondingly greater increases in areal bone mineral density (aBMD) at all skeletal sites. Denosumab was approved by FDA in June 2010 for the treatment of postmenopausal women with osteoporosis at high risk of fracture. Denosumab (Prolia®) is also licensed in Hong Kong.

A high-resolution peripheral quantitative computed tomography (HR-pQCT) capable of achieving an isotropic voxel size of 80μm at tolerable radiation doses (3μSv) is available for the assessment of trabecular and cortical microarchitecture at the distal radius and tibia. This technique bears excellent precision for both density and microstructure measures. Denosumab's greater potency in suppressing bone remodeling and greater effect on areal BMD than alendronate, particularly at predominantly cortical sites such as the distal third of the radius, may reflect the differing mechanism of action of these drugs, which, in turn, influence bone microarchitecture.

The aim of this study is to compare the effects of denosumab and a current standard treatment on cortical and trabecular microarchitecture at the radius and second metacarpal in RA patients with low bone mineral density using HR-pQCT during a 6-month open-label randomized controlled study. One bisphosphonate, namely alendronate sodium (or alendronate) is chosen to generate a heterogeneous and comparable active control group. This is a 6-month open-label randomized controlled clinical trial. Forty ambulatory Chinese females, who consent to receive alendronate as standard treatment subjective to the randomization, will be enrolled from the rheumatology clinic of the Prince of Wales Hospital in this study. Subjects will be randomized to 2 groups receiving: 1) subcutaneous injection of denosumab 60mg (Prolia®) every 6 months (n=20), or 2) a standard treatment: oral alendronate weekly (Fosamax® once weekly 70 mg, n=20). In addition, all patients will be given a daily calcium supplement (1500mg caltrate /day) and 1 multivitamin tablet per day. Efficacy and safety assessment will be performed at baseline, month 3 and month 6. aBMD of lumbar spine, total hip and non-dominant distal radius will be measured using dual-energy X-ray absorptiometry (DXA) and microarchitecture of bone is measured at the non-dominant distal radius and the second metacarpal bone of the non-dominant hand using HR-pQCT.
Participants aged 50-65 years who declined the initial offer of FIT, will complete a 10-15 minute questionnaire about their personal health, quality of life, and health-related to colorectal cancer including screening history and smoking. Participants will be in this group for up to 6 months.
BACKGROUND AND OBJECTIVES: Autoantibody discovery in complex autoimmune diseases is challenging. Diverse successful antigen identification strategies are available, but, so far, have often been unsuccessful, especially in the discovery of protein antigens in which conformational and post-translational modification are critical. Our study assesses the utility of a human membrane and secreted protein microarray technology to detect autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
METHODS: A cell microarray consisting of human embryonic kidney-293 cells expressing >5,000 human proteins was used. First, a validation step was performed with 4 serum samples from patients with autoimmune nodopathy (AN) to assess the ability of this technology to detect circulating known autoantibodies. The ability of the cell microarray technology to discover novel IgG autoantibodies was assessed incubating the array with 8 CIDP serum samples. Identified autoantibodies were subsequently validated using cell-based assays (CBAs), ELISA, and/or tissue immunohistochemistry and analyzed in a cohort of CIDP and AN (n = 96) and control (n = 100) samples.
RESULTS: Serum anti-contactin-1 and anti-neurofascin-155 were detected by the human cell microarray technology. Nine potentially relevant antigens were found in patients with CIDP without other detectable antibodies; confirmation was possible in six of them: ephrin type-A receptor 7 (EPHA7); potassium-transporting ATPase alpha chain 1 and subunit beta (ATP4A/4B); leukemia-inhibitory factor (LIF); and interferon lambda 1, 2, and 3 (IFNL1, IFNL2, IFNL3). Anti-ATP4A/4B and anti-EPHA7 antibodies were detected in patients and controls and considered unrelated to CIDP. Both anti-LIF and anti-IFNL antibodies were found in the same 2 patients and were not detected in any control. Both patients showed the same staining pattern against myelinating fibers of peripheral nerve tissue and of myelinating neuron-Schwann cell cocultures. Clinically relevant correlations could not be established for anti-LIF and anti-IFNL3 antibodies.
DISCUSSION: Our work demonstrates the utility of human cell microarray technology to detect known and discover unknown autoantibodies in human serum samples. Despite potential CIDP-associated autoantibodies (anti-LIF and anti-IFNL3) being identified, their clinical and pathogenic relevance needs to be elucidated in bigger cohorts.
<P>PROBLEM TO BE SOLVED: To determine a nucleotide sequence and an amino acid sequence of an antigen detected by MCA 44-3A6.  <P>SOLUTION: A cDNA molecule that encodes a protein designated Labyrinthin (Lab) is isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define new classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab.  <P>COPYRIGHT: (C)2009,JPO&INPIT
The invention discloses a pig Ghrelin derivative and coded genes and uses thereof. The pig Ghrelin derivative is a polypeptide at least comprising GSSF or GSWF amino acid residue sequence derived from pig Ghrelin. The invention also provides a polypeptide medicine and a gene medicine. The active constituent of said polypeptide medicine is the pig Ghrelin derivative or its soluble salt. The active constituent of said gene medicine is the coded gene of the pig Ghrelin derivative. The pig Ghrelin derivative, coded genes thereof and medicines using the genes as active constituents can be used in livestock and fowl production and clinical gene supplement and substitution treatment.
PURPOSE:To provide an MRI opaque substance which has a sufficient opaque capacity in a physiologically permitted opaque substance concn. region and with which useful image information is obtainable by using a polyamine metal complex compd. formed by coordinate bond of a polyamine ligand having <19>F to paramagnetic metal ions as a compd. having opaque activity. CONSTITUTION:This opaque substance consists of the polyamine metal complex compd. formed by coordinate bond of the polyamine ligand having >=1 fluorine atoms to the paramagnetic metal ions. The paramagnetic metal is selected from a group consisting of chromium, manganese, iron, copper and gadolinium. The NMR chemical shifts of the plural fluorine atoms are all substantially the same and are all distributed within the region of <=2000Hz width. On the other hand, a tissue specific material having specific affinity to the specific biotissue to be opacified is bonded via an adequante linker to the polyamine ligand. The tissue specific material is peptide and/or material contg. saccharides, monoclonal antibody.
BACKGROUND: Schwannomas are benign, slow-growing encapsulated nodular lesions. As for the most benign encapsulated lesions, the treatment of choice is complete removal of the entire tissue with preservation of surrounding tissue.
METHODS AND RESULTS: The case presented is that of a 35-year-old female with the chief complaint of swelling on her gums in the lower left posterior region. Through intraoral and extraoral examinations the benign nature of the lesion was established. The excisional biopsy was carried out under local anesthesia, and the specimen was sent for histological examination, which gave a definite diagnosis of oral schwannoma. The patient was recalled at regular intervals so as to check for any recurrence of the lesion or occurrence of new lesions elsewhere in the body.
CONCLUSION: The present case reemphasizes the importance of thorough clinical examination along with appropriate investigations, especially histopathological and immunohistochemical, for establishing a definitive diagnosis, which eventually plays an important role in the choice and execution of appropriate treatment at the earliest for the best prognosis and outcomes.
KEY POINTS: Why is this case new information? To the best of the author's knowledge, this the first case report of oral schwannoma diagnosed in gingiva in Indian population. This case presented a diagnostic dilemma due to its unusual location. What are the keys to successful management of this case? Schwannomas when completely excised have low rate of recurrence. Accurate diagnosis of the lesion along with complete physical examination and follow-up at regular interval to rule out any recurrences are the keys to successful management of this case. What are the primary limitations to success in this case? Lack of data regarding residual tumor postoperative is a primary limitations to success of the case, as recurrence is associated with subtotal tumor removal.
The NeuroLife EMG-FES System is a completely non-invasive system (surface electrodes only, no implantable components) worn on the forearm of participants and has up to 160 electrodes that can record electromyography (EMG), or muscle activity, and also electrically stimulate (FES) muscles. Using this combined, closed-loop technology participants will complete a 12-week protocol with a study therapist practicing functional activities using their hand/forearm while wearing the NeuroLife EMG-FES Sleeve System.
PROBLEM TO BE SOLVED: To obtain a gel composition useful as a filler for a soft gelatin capsule pharmaceutical preparation, a carrier, etc., for a drug of topical formulation by using calcium acetate which is a gelling agent in a polyethylene glycol having a specific average molecular weight and water. SOLUTION: This gel composition contains a polyethylene glycol having an average molecular weight of 600 or below, water and calcium acetate in an amount effective in gelation of the polyethylene glycol. An effective amount of a drug can further be dissolved or suspended in the gel composition. For example, acetaminophen, famotidine, chlorphenyramine and pseudoephedrin are cited as the drug. The get composition can be used as a cosmetic or a care product for teeth. The calcium acetate which is the gelling agent is preferably used as the form of an aqueous solution and is capable of spontaneously making the liquid polyethylene glycol gel at ambient temperature. Since the method does not require heating or cooling, a production process is simple at a low cost.
The invention provides an application of a PD-1 inhibitor and a STING stimulant in tumor treatment, belonging to the technical field of medicines. According to the invention, through research, both the PD-1 inhibitor (BMS1166) and the STING agonist (DMXAA) can effectively inhibit the cell proliferation of DLBCL. DMXAA induces the activation of cGAS/STING pathway, and promotes DLBCL cells to highly express STING. The increased STING expression can promote the expression of PD-L1, and further enhance the inhibition of BMS1166 on cell activity. Therefore, BMS1166 and DMXAA can produce synergistic effect and play more significant anti-tumor effect. The invention provides technical support for enhancing the treatment response of the PD-1 inhibitor in DLBCL and optimizing the treatment scheme of the PD-1 inhibitor.
Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.